Skip to main content
Top
Published in: European Radiology 5/2021

01-05-2021 | Opioids | Gastrointestinal

Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma

Authors: Atanas Pachev, Lucas Raynaud, Luisa Paulatto, Marco Dioguardi Burgio, Vincent Roche, Carmela Garcia Alba, Annie Sibert, Matthieu Lagadec, Juliette Kavafyan-Lasserre, Catherine Paugam-Burtz, Valérie Vilgrain, Maxime Ronot

Published in: European Radiology | Issue 5/2021

Login to get access

Abstract

Objectives

To prospectively assess the frequency of severe abdominal pain during and after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the visual analog scale (VAS), and to identify predictive factors.

Methods

Ninety-eight TACE performed in 80 patients (mean 65 ± 12 years old, 60 men) were consecutively and prospectively included. Abdominal pain was considered severe if the VAS ≥ 30/100 after treatment administration, or if opioid analgesic (grades 2–3) intake was required during hospitalization. Patient and tumor characteristics as well as technical factors associated with severe pain were identified by binary logistic regression.

Results

The criterion for severe pain was met in 41/98 (42%) of procedures (peri-procedural pain 30/98 [31%] and opioid consumption during hospitalization 24/98 [25%]). Multivariate analysis identified age (odds ratio [OR] = 0.943 (95% confidence interval 0.895–0.994), p = 0.029), cirrhosis (OR = 0.284 (0.083–0.971), p = 0.045), and alcoholic liver disease (OR = 0.081 (0.010–0.659), p = 0.019) as negative predictive factors of severe abdominal pain. Severe abdominal pain occurred in or after 1/13 (8%), 8/34 (24%), 22/41 (54%), and 10/10 (100%) TACE sessions when none, one, two, and three of the protective factors were absent, respectively (p < 0.001). The area under the ROC curve of the combination of factors for the prediction of severe abdominal pain was 0.779 (CI 0.687–0.871).

Conclusion

Severe abdominal pain was frequent during and after TACE revealing a clinically relevant and underestimated problem. A predictive model based on three readily available clinical variables suggests that young patients without alcoholic liver disease or cirrhosis could benefit from reinforced analgesia.

Key Points

• Severe abdominal pain occurs in 43% of TACE for HCC.
• Younger age, absence of cirrhosis, and absence of alcoholic liver disease were identified as independent predictive factors of severe abdominal pain.
• A simple combination of the three abovementioned features helped predict the occurrence of severe abdominal pain.
Appendix
Available only for authorised users
Literature
1.
go back to reference Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314CrossRef Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314CrossRef
2.
go back to reference European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236 European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
3.
go back to reference Otto G, Herber S, Heise M et al (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12:1260–1267CrossRef Otto G, Herber S, Heise M et al (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12:1260–1267CrossRef
4.
go back to reference Ravaioli M, Grazi GL, Piscaglia F et al (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8:2547–2557CrossRef Ravaioli M, Grazi GL, Piscaglia F et al (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8:2547–2557CrossRef
5.
go back to reference Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRef Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRef
6.
go back to reference Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRef Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRef
7.
go back to reference Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRef Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRef
9.
go back to reference Pomoni M, Malagari K, Moschouris H et al (2012) Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology 59:820–825PubMed Pomoni M, Malagari K, Moschouris H et al (2012) Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology 59:820–825PubMed
10.
go back to reference Bouvier A, Ozenne V, Aube C et al (2011) Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 21:1719–1726CrossRef Bouvier A, Ozenne V, Aube C et al (2011) Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 21:1719–1726CrossRef
11.
go back to reference Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRef Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRef
12.
go back to reference Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC (2001) Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12:321–326 Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC (2001) Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12:321–326
13.
go back to reference Benzakoun J, Ronot M, Lagadec M et al (2017) Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int 37:583–591CrossRef Benzakoun J, Ronot M, Lagadec M et al (2017) Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int 37:583–591CrossRef
14.
go back to reference Lang EV, Benotsch EG, Fick LJ et al (2000) Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet 355:1486–1490CrossRef Lang EV, Benotsch EG, Fick LJ et al (2000) Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet 355:1486–1490CrossRef
15.
go back to reference European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines: management of alcohol-related liver disease. J Hepatol 69:154–181 European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines: management of alcohol-related liver disease. J Hepatol 69:154–181
16.
go back to reference Yang H, Seon J, Sung PS et al (2017) Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma: a randomized, double-blinded, placebo-controlled study. J Vasc Interv Radiol 28:1503–1511 e1502CrossRef Yang H, Seon J, Sung PS et al (2017) Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma: a randomized, double-blinded, placebo-controlled study. J Vasc Interv Radiol 28:1503–1511 e1502CrossRef
17.
go back to reference Guo JG, Zhao LP, Rao YF et al (2018) Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 17:510–516CrossRef Guo JG, Zhao LP, Rao YF et al (2018) Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 17:510–516CrossRef
18.
go back to reference Jensen KJ, Alpini G, Glaser S (2013) Hepatic nervous system and neurobiology of the liver. Compr Physiol 3:655–665CrossRef Jensen KJ, Alpini G, Glaser S (2013) Hepatic nervous system and neurobiology of the liver. Compr Physiol 3:655–665CrossRef
19.
go back to reference Novak DJ, Victor M (1974) The vagus and sympathetic nerves in alcoholic polyneuropathy. Arch Neurol 30:273–284CrossRef Novak DJ, Victor M (1974) The vagus and sympathetic nerves in alcoholic polyneuropathy. Arch Neurol 30:273–284CrossRef
20.
go back to reference Lammer J, Malagari K, Vogl T et al (2009) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52CrossRef Lammer J, Malagari K, Vogl T et al (2009) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52CrossRef
22.
go back to reference Wang TC, Zhang ZS, Xiao YD (2020) Determination of risk factors for pain after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Pain Res 13:649–656CrossRef Wang TC, Zhang ZS, Xiao YD (2020) Determination of risk factors for pain after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Pain Res 13:649–656CrossRef
23.
go back to reference Hatsiopoulou O, Cohen RI, Lang EV (2003) Postprocedure pain management of interventional radiology patients. J Vasc Interv Radiol 14:1373–1385CrossRef Hatsiopoulou O, Cohen RI, Lang EV (2003) Postprocedure pain management of interventional radiology patients. J Vasc Interv Radiol 14:1373–1385CrossRef
24.
go back to reference Schupp CJ, Berbaum K, Berbaum M et al (2005) Pain and anxiety during interventional radiologic procedures: effect of patients’ state anxiety at baseline and modulation by nonpharmacologic analgesia adjuncts. J Vasc Interv Radiol 16:1585–1592CrossRef Schupp CJ, Berbaum K, Berbaum M et al (2005) Pain and anxiety during interventional radiologic procedures: effect of patients’ state anxiety at baseline and modulation by nonpharmacologic analgesia adjuncts. J Vasc Interv Radiol 16:1585–1592CrossRef
Metadata
Title
Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma
Authors
Atanas Pachev
Lucas Raynaud
Luisa Paulatto
Marco Dioguardi Burgio
Vincent Roche
Carmela Garcia Alba
Annie Sibert
Matthieu Lagadec
Juliette Kavafyan-Lasserre
Catherine Paugam-Burtz
Valérie Vilgrain
Maxime Ronot
Publication date
01-05-2021
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 5/2021
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-07404-5

Other articles of this Issue 5/2021

European Radiology 5/2021 Go to the issue